Schematic representation of the experimental design. huRANKL mice were ovariectomized (OVX) or not (Sham) at 18 weeks of age and assigned to receive either Veh, Aln, or DMAb treatment. After 4 weeks, mice were further assigned to intermittent PTH (1–34) (80 μg/kg/day) or Veh administration, in addition to Aln, DMAb, or Veh.